Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Long-term safety of momelotinib for myelofibrosis

Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, outlines the long-term safety of momelotinib in myelofibrosis patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).